A Multicenter, Randomized, Placebo-Controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Ascending Subcutaneous Doses of GS-0272 in Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus (MARASLE)
Latest Information Update: 07 May 2025
At a glance
Most Recent Events
- 13 Jun 2024 Planned number of patients changed from 48 to 87.
- 13 Jun 2024 Systemic lupus erythematosus has been removed from indications. The study drug will be administered by Intravenous route also only for part B of the study.
- 09 Oct 2023 Status changed from not yet recruiting to recruiting.